GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (STU:2B30) » Definitions » Total Equity

Xeris Biopharma Holdings (STU:2B30) Total Equity : €-28.3 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xeris Biopharma Holdings Total Equity?

Xeris Biopharma Holdings's total equity for the quarter that ended in Dec. 2024 was €-28.3 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Xeris Biopharma Holdings Total Equity Historical Data

The historical data trend for Xeris Biopharma Holdings's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Total Equity Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only 27.75 84.28 42.66 -6.22 -28.28

Xeris Biopharma Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.22 -8.44 -17.92 -25.52 -28.28

Xeris Biopharma Holdings Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Xeris Biopharma Holdings's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=308.522-336.805
=-28.3

Xeris Biopharma Holdings's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=308.522-336.805
=-28.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings Total Equity Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (STU:2B30) » Definitions » Total Equity
Comparable Companies
ZYME PHVS RCUS GYRE NTLA DAWN RCKT REPL VIR MLYS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
XERS:USA 0A8E:UK 2B30:Germany
Address
1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Website
https://www.xerispharma.com
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings Headlines

No Headlines